Clinical trial
Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures
NCT00042081 · Anesiva, Inc., Industry · Completed
Key facts
| NCT number | NCT00042081 |
|---|---|
| Title | Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures |
| Official title | A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Coronary Vein Grafts in Patients Undergoing Coronary Artery Bypass Graft Procedures |
| Lead sponsor | Anesiva, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Coronary Artery Disease |
| Intervention type | Drug |
| Interventions | CGT003 (E2F Duplex Decoy) |
| Enrollment | 3,000 |
| Start date | Jul 1, 2002 |
| Completion | Feb 1, 2005 |
| First posted | Jul 24, 2002 |
| Last update posted | May 5, 2006 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: